17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit against five companies over the development of Brenzys, an etanercept biosimilar, in Australia.

Pfizer and its subsidiary Hospira were previously involved in a patent dispute over the development and marketing of its biosimilars referencing Neupogen (filgrastim) and Neulasta (pegfilgrastim), both of which were developed by Amgen and are used to treat patients undergoing chemotherapy who are at risk of developing febrile neutropenia.

Read Center for Biosimilars article